Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2015

01.11.2015 | Laboratory Investigation

Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors

verfasst von: Marc C. Chamberlain, Donald Born

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

1p/19q codeletion is a favorable prognostic marker for oligodendroglial tumors (OT). Compare outcome in OT with simple deletions of 1p or 19q to those with relative deletions defined as the presence of both increased copy number (polysomy) and 1p/19q codeletion. 525 cases were examined by fluorescence in situ hybridization (FISH) using dual color probes to determine the deletion status of chromosome arms 1p and 19q. Categories included simple deletions defined as a proportion of either 1p32 or 19q13 FISH signals compared to 1q42 or 19p13 signals less than 0.80 and relative deletions (1p or 19q) defined as the combination of a <0.80 proportion with >30 % of nuclei showing increased chromosome number (based on enumeration of 1q25 or 19p13). 464 (80 %) were WHO Grade II or III OT of which 209 (48 %) had both 1p and 19q deleted (codeletion). 72 (16 %) had relative deletions for either one or both 1p and 19q of which 28 (6 %) had relative deletions of 1p and 19q (relative codeletion). Overall survival in WHO Grade II OT was 13 + years when 1p/19q codeleted (n = 156); 5 + years in uni- or nondeleted (n = 86); 6 + years in relative deletion for either 1p or 19q (n = 41); and 6 + years in relative 1p/19q codeletion (n = 15). Similarly in WHO Grade III OT (n = 168) overall survival was 11 + years in 1p/19q codeleted (n = 54) OT; 2.5 years in uni- or nondeleted (n = 70); 3 years in relative deletion for one or both 1p or 19q (n = 31); and 4 + years in relative 1p/19q codeletion (n = 13). Survival for OT regardless of grade with relative codeletion of 1p/19q was approximately one half that of 1p/19q codeleted tumors. The presence of relative 1p/19q codeletion is of prognostic significance.
Literatur
1.
Zurück zum Zitat Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479CrossRefPubMed
2.
Zurück zum Zitat Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefPubMed Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefPubMed
3.
Zurück zum Zitat Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed Cairncross G, Wang M, Shaw E, Jenkins R et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350CrossRefPubMed van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350CrossRefPubMed
5.
Zurück zum Zitat Buckner J, Shaw E, Pugh S, et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: Results by histologic type. Neuro Oncol 2014;16 (suppl5): AT-13. Abstract Buckner J, Shaw E, Pugh S, et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: Results by histologic type. Neuro Oncol 2014;16 (suppl5): AT-13. Abstract
6.
Zurück zum Zitat Snuderl M, Echler AF, Ligon KL et al (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15:6430–6437PubMedCentralCrossRefPubMed Snuderl M, Echler AF, Ligon KL et al (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15:6430–6437PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Al Wiens, Cheng L, Bertsch EC et al (2012) Polysomy of chromosomes 1 and or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol 71:618–624CrossRef Al Wiens, Cheng L, Bertsch EC et al (2012) Polysomy of chromosomes 1 and or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol 71:618–624CrossRef
8.
Zurück zum Zitat Ren X, Jiang H, Cui X et al (2013) Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol 15:1244–1250PubMedCentralCrossRefPubMed Ren X, Jiang H, Cui X et al (2013) Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol 15:1244–1250PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S (2014) Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neurooncol 120:131–138CrossRefPubMed Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S (2014) Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neurooncol 120:131–138CrossRefPubMed
10.
Zurück zum Zitat Reifenberger G, Kros JM, Louis DN et al (2007) Oligodendroglioma and anaplastic oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, France, pp 54–62 Reifenberger G, Kros JM, Louis DN et al (2007) Oligodendroglioma and anaplastic oligodendroglioma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, France, pp 54–62
11.
Zurück zum Zitat Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314–322PubMed Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314–322PubMed
12.
Zurück zum Zitat Weller M, Wick W (2014) Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 10:68–70CrossRefPubMed Weller M, Wick W (2014) Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol 10:68–70CrossRefPubMed
Metadaten
Titel
Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors
verfasst von
Marc C. Chamberlain
Donald Born
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1906-y

Weitere Artikel der Ausgabe 2/2015

Journal of Neuro-Oncology 2/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.